NDC 51662-1291-2 - DOPAMINE HCI
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 51662-1291
- Requested NDC
- 51662-1291-2
- Package NDCs from labels
- 51662-1291-1, 51662-1291-2, 51662-1291-3
- Manufacturer
- HF Acquisition Co LLC, DBA HealthFirst
- Effective date
- 2024-02-22
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| DOPAMINE HCI - HF Acquisition Co LLC, DBA HealthFirst | HF Acquisition Co LLC, DBA HealthFirst | 2024-02-22 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 51662-1291-1 | 2020-02-07 | C162847 | 48780-1 | 9d75b9d0-bbd2-f424-e053-dadaa90a57ce | DOPAMINE HCI INJ., USP 200mg (40 mg/mL) 5mL VIAL |
| 51662-1291-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-bbd2-f424-e053-dadaa90a57ce | DOPAMINE HCI INJ., USP 200mg (40 mg/mL) 5mL VIAL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51662-1291-1 | DOPAMINE HCI | 5 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION, CONCENTRATE | 5 | 7 | |
| 51662-1291-2 | DOPAMINE HCI | 1 in 1 POUCH | INJECTION, SOLUTION, CONCENTRATE | 1 | 7 | |
| 51662-1291-2 | DOPAMINE HCI | 5 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION, CONCENTRATE | 5 | 7 | |
| 51662-1291-3 | DOPAMINE HCI | 25 in 1 CASE | INJECTION, SOLUTION, CONCENTRATE | 25 | 7 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51662-1291 | DOPAMINE HCI INJECTION, SOLUTION, CONCENTRATE [HF ACQUISITION CO LLC, DBA HEALTHFIRST] | 7 | Current NDC, Legacy NDC, 4 package rows | 20240224_763d2b07-9cea-782e-e053-2a91aa0adc01.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| InterSol | PLATELET ADDITIVE 3 | Fenwal, Inc. | e4f06c0b-7cb1-49c9-97a4-2cfc21298495 | 2021-11-16 | Warnings, Adverse reactions | B22547B95K |
| Solucion InterSol | SOLUCION ADITIVA PARA PLAQUETAS 3 | Fenwal, Inc. | d5eaf5f4-67d3-4475-af9a-f5b0f882f5d1 | 2021-10-04 | Warnings, Adverse reactions | B22547B95K |
| Dopamine Hydrochloride and Dextrose | DOPAMINE HYDROCHLORIDE | Baxter Healthcare Corporation | cb97d4a0-89ed-407c-a763-209386b6f75c | 2020-11-11 | Warnings, Adverse reactions | 7L3E358N9L |
| InterSol | PLATELET ADDITIVE 3 | Fenwal, Inc. | a00c4a93-cde2-4753-81f7-0d6fee9fb690 | 2020-10-20 | Warnings, Adverse reactions | B22547B95K |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | XF417D3PSL B22547B95K | |
| Renacidin | CITRIC ACID, GLUCONOLACTONE AND MAGNESIUM CARBONATE | United-Guardian, Inc. | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 | 2019-12-17 | Warnings, Adverse reactions | XF417D3PSL |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | XF417D3PSL B22547B95K | |
| Dopamine | DOPAMINE HYDROCHLORIDE | BioActive Nutritional | 2e456b07-8b7b-463a-8cf5-1d7a51985b06 | 2016-08-16 | Warnings | 7L3E358N9L |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 051f7347-5a76-4664-8fe2-e61b3dfcb0e4 | 2014-08-27 | XF417D3PSL B22547B95K |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.